Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 39, 4378-4380, November 1, 1979]
© 1979 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vesselinovitch, S. D.
Right arrow Articles by Mihailovich, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vesselinovitch, S. D.
Right arrow Articles by Mihailovich, N.

Transplacental and Lactational Carcinogenesis by Safrole1

S. D. Vesselinovitch, K. V. N. Rao and N. Mihailovich

Departments of Pathology [S. D. V.] and Radiology [S. D. V., K. V. N. R., N. M.], The Pritzker School of Medicine, and the Franklin McLean Memorial Research Institute [S. D. V.], University of Chicago, Chicago, Illinois 60637

The carcinogenicity of safrole following transplacental exposure of the mouse fetus and exposure of the neonatal mouse via the mother's milk was investigated in C57BL/6J x C3HeB/FeJ F1 (hereafter called B6C3F1) mice by intragastric administration of the agent to pregnant and lactating C57BL/6J females. Safrole (120 µg/g body weight per treatment) was administered to (a) pregnant mice (4 times on Days 12, 14, 16, and 18 of gestation); (b) lactating mothers (12 times every second day following parturition); or (c) 4-week-old offspring (180 times twice weekly for 90 weeks). Two additional groups of offspring received a, b, and a, b, and c combination treatments. All survivors were killed at 94 weeks of age. Renal epithelial tumors were observed in 7% of female offspring exposed to safrole in utero; none of the other experimental and control animals developed these tumors. Only male offspring nursed during the preweaning period by mothers treated with safrole developed hepatocellular tumors (34%). In contrast, direct administration of safrole, beginning at the time of weaning and continuing for the duration of experiment, led to a significantly high incidence of hepatocellular tumors in females (48%), but not in males (8%). Eighty-six % of the liver tumors observed in females were hepatocellular carcinomas with a high rate of pulmonary metastases (42%). The data suggest that safrole or its metabolites came into contact with fetuses by crossing the placenta and with infants through its excretion in milk to exert the perinatal carcinogenicity.

1 This investigation was supported in part by NIH Contract N01-CP-43317 from the National Cancer Institute. Preliminary information on the content of this paper has been presented in part at the Conference on Perinatal Carcinogenesis held in Tampa, Fla., January 19 to 21, 1976 (13).

Received 5/14/79. Accepted 8/ 6/79.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1979 by the American Association for Cancer Research.